NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

McDonagh M. Drug Class Review: Disease-Modifying Drugs for Multiple Sclerosis: Single Drug Addendum: Fingolimod: Final Original Report [Internet]. Portland (OR): Oregon Health & Science University; 2011 Feb.

Cover of Drug Class Review: Disease-Modifying Drugs for Multiple Sclerosis: Single Drug Addendum: Fingolimod

Drug Class Review: Disease-Modifying Drugs for Multiple Sclerosis: Single Drug Addendum: Fingolimod: Final Original Report [Internet].

Show details

Conclusions

In patients with relapsing-remitting multiple sclerosis, fingolimod 0.5 mg and 1.25 mg once daily was superior to interferon beta-1a in improving relapse-related outcomes, including annualized relapse rates and proportion without relapse, over a 1 year period. Progression of disability was not different between the treatments. The higher dose (1.25 mg once daily) of fingolimod resulted in higher numbers and more severe adverse events, including herpes zoster infections and symptomatic bradycardia after the first dose, as well as more patients discontinuing treatment. Differences in adverse events between 0.5 mg fingolimod and interferon beta-1a were limited to more patients with pyrexia, myalgia, and flu-like symptoms with interferon and more with elevated liver enzymes with fingolimod. Ongoing concerns with the safety of fingolimod included the risk of macular edema, the effect of lung function, cancers, and serious viral infections. Further studies are underway to better determine the risk with fingolimod.

Copyright © 2011 by Oregon Health & Science University.
Bookshelf ID: NBK65424
PubReader format: click here to try

Views

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...